Genitourinary Steering Committee (GUSC) Update

Clinical Trials and Translational Research Advisory Committee Meeting July 15, 2009

George Wilding, M.D.

GUSC Co-Chairs

Eric Klein, M.D. Cleveland Clinic Urology

George Wilding, M.D. Univ. of Wisconsin Carbone Cancer Center Medical Oncology

> Anthony Zietman, M.D. Massachusetts General Hospital *Radiation Oncology*

GUSC Members

Michael Atkins, M.D. Donna Berry, Ph.D., R.N. **Bobbi Brady** William Dahut, M.D. Colin Dinney, M.D. Robert DiPaola, M.D. Jan Dutcher, M.D. **Boris Freidlin, Ph.D.** Susan Halabi, Ph.D. Philip Kantoff, M.D. Adam Kibel, M.D. Bhupinder Mann, M.D.

Margaret Mooney, M.D. Ken Pienta, M.D. Hank Porterfield Seth Rosenthal, M.D. Howard Sandler, M.D. Paul Schultz, M.D. Neal Shore, M.D. Eric Small, M.D. Cathy Tangen, Ph.D. lan Thompson, Jr., M.D. Fred Waldman, M.D., Ph.D. Benjamin Yeh, M.D.

SC Representatives

Bladder SPORE - 1 Community Medical Oncologists - 2 Community Radiation Oncologist - 1 Community Urologist - 1 Cooperative Group Disease Chairs - 6 Extramural Statisticians - 2 NCI Extramural Staff - 3 NCI Intramural staff - 1 Patient Advocates - 2 **Prostate SPORES - 2 Renal SPORE - 1** Translational P01/R01Scientists - 2

Institutional Affiliations

Alliance for Prostate Cancer Prevention Beth Israel Deaconess Medical Center Brigham and Women's Hospital Carolina Urologic Research Center Cedars-Sinai Medical Center

Cleveland Clinic Dana Farber Cancer Institute Duke University Medical Center Fred Hutchinson Cancer Research Center Life with Cancer Advisory Council Massachusetts General Hospital MD Anderson Cancer Center **Missouri Baptist Cancer Center** Montefiore Medical Center, Bronx, NY **National Cancer Institute** Radiation Oncology Center, Roseville, CA Univ. of Medicine & Dentistry of New Jersev University of California, San Francisco **University of Michigan** Univ. of Wisconsin Carbone Cancer Center **University of Montreal UTHSC-San Antonio** Washington University

Cooperative Group Affiliations

Twenty four members list memberships in one or more Cooperative Groups:

ACRIN

CALGB

ECOG

NSABP (community oncology member)

NCIC

RTOG

SWOG

Timeline

February 2008 - Intergroup Transition Meeting
August 2008 - First Concept Reviewed
February 2009 - Prostate TF Formed
February 2009 - Face to Face at GU ASCO
Summer 2009 - Renal and Bladder TFs Forming



Evaluated - 6

- Approved 2
- Revise and Resubmit 1
- Disapprove 1
- In progress 2

Approved Concepts

RTOG 0815-A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

Localized prostatic adenocarcinoma at intermediate risk for recurrence as determined by harboring one or more of the following intermediate-risk features: Gleason Score 7; PSA >10, \leq 20; T-Stage T2b-T2c. Patients harboring all three of these risk factors who also have \geq 50% of their biopsy cores positive will be ineligible for this trial.

RTOG 0815-A

2. ACE-27 score < 2	
F 3. EBRT + HDR brachytherapy I Y boost Z Intermediate risk factors: Gleason Score 7: PSA >10, <	Arm 2 Dose-escalated RT combined with short-term (6 months) androgen blockade (LHRH agonist + antiandrogen)


Intermediate risk factors: Gleason Score 7; PSA >10, \leq 20; FStage T2b-T2c. *Patients with all three intermediate risk factors and \geq 50% of their sampled biopsy cores involved will <u>not</u> be eligible for this study.

Approved Concepts

CALGB-90802 Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors

Metastatic clear cell renal carcinoma who have had progressed on at least 1 prior VEGFR TKI therapies (no prior VEGFR binding agents or mTOR inhibitors allowed). Adequate organ function and ECOG PS 0-2 required.

CALGB-90802



5.2 Arms/Regimens

Each cycle is 28 days (4 weeks)

	AGENT	DOSE	ROUTE	SCHEDULE
ARM A	Everolimus	10 mg	PO	Daily
	Placebo		IV	D1 and D15
ARM B	Everolimus	10 mg	РО	Daily

Bevacizumab 10 mg/kg IV D1 and D15

Prostate Task Force Co-Chairs

Michael Carducci, M.D. Johns Hopkins Medical Oncology

Deborah A. Kuban, M.D. MD Anderson Cancer Center Radiation Oncology

Andrew Stephenson, M.D. Cleveland Clinic Urology

Prostate Task Force Members

Sam Chang, Vanderbilt Kim Chi, U. of British Columbia Neil Fleshner, Princess Margaret James Gulley, NCI Maha Hussain, Univ. of Michigan Kevin Kelly, Yale W. Robert Lee, Duke Glenn Liu, Univ. of Wisconsin Jeff Michalski, Washington Univ. Jim Mohler, Roswell Park Charles Ryan, UCSF Howard Scher, MSKCC/ PCCTC Robert Uzzo, Fox Chase

Prostate Task Force

- Formed January 2008
- Interacts with the IDSC and Investigational Drug Branch; Providing advice on several prostate specific agents
- Establishing a working group to develop a Clinical Trials Planning Meeting submission
- CRF Harmonization Working Group
 - Has met twice
 - Inventorying group's CRF
 - Working with CaBIG



- Established Steering Committee and Operating Procedures
- Initiated Concept Reviews
- Created Prostate Cancer Task Force
- Developed Reconciliation Procedure
- Started New Drug CTEP/Industry Advisory Process
- Arrived at Consensus Expectations
- Androgen Receptor Targeting
- Multiple new therapies in prostate and renal cancers

Challenges

- Intergroup cooperativeness
- Cooperative Group confidence in grant review expectations

New Clinical Research Opportunities in GU Oncology

Androgen Receptor Targeting

• Multiple new therapies in prostate and renal cancers

Goals for Upcoming Year

- Organize clinical trial planning meeting targeting the androgen receptor
- Create renal and bladder task forces